Spotlight on Oncology
Optimizing Treatment of B-Cell Non-Hodgkin Lymphomas in the Modern Era - Part B
StartActivity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
0.5 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with B-Cell Non-Hodgkin Lymphomas.
Learning Objectives
After completing this program, participants should be able to:
- Summarize current evidence-based management strategies for treating B-cell NHLs with newer agents and combination approaches
- Evaluate safety and efficacy data from recent clinical trials and its impact on future clinical practice
- Formulate individualized strategies for incorporating new agents and regimens into the evolving treatment paradigms for B-cell NHLs, taking into consideration current guidelines, expert recommendations, and clinical factors
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of B-Cell Non-Hodgkin Lymphomas. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for B-Cell Non-Hodgkin Lymphomas along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with B-Cell Non-Hodgkin Lymphomas, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Co-Director Lymphoma Program
Winship Cancer Institute
Emory University
Atlanta, GA
Conflict of Interest Policy/Disclosure Statement
Dr. Cohen has served on advisory boards for Janssen and Genentech and has done research funding for Genentech.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is
jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE),
and the American Nurses Credentialing Center (ANCC), to provide continuing
education for the healthcare team.
This activity is being presented without bias and with commercial
support.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians
should claim only credit commensurate with the extent of their participation
in the activity.
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a
maximum of 0.5 continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
Supported by educational grant from AbbVie Inc., Bayer HealthCare Pharmaceutical Inc., Celgene Corp., Janssen Biotech, Inc., and Verastem.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Oncology Presentations
Navigating the Continuum of Care for Advanced Prostate Cancer (mHSPC, CRPC)
StartActivity Details
1.0 Contact Hour(s)
Expires: February 17, 2022
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Explain the different treatment modalities for treating advanced and metastatic prostate cancer including hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies
- Describe and implement the latest advances in the management of advanced prostate cancer across the disease continuum
- Personalize treatment decisions for patients with advanced and metastatic prostate cancer based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementadvanced prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the exception of skin cancer, prostate cancer remains the most common cause of cancer in American men. The majority of patients diagnosed will seek treatment through surgery or radiation, and among those patients, approximately one-third will experience disease recurrence as indicated by elevated prostate specific antigen (PSA). Although androgen deprivation therapy (ADT) achieves temporary tumor control or regression in 90% of these individuals, most patients will ultimately progress to the advanced and/or fatal stage of malignancy, known as castrate-resistant prostate cancer (CRPC), in which the disease spreads to the regional lymph nodes, seminal vesicles, and distant sites such as the bones.
In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Many agents have received FDA approval for the treatment of advanced prostate cancer, including early taxanes, novel endocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel targeted therapies. These agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm, either alone or in combination, in an effort to prolong survival while maintaining the patients’ quality of life. Other novel agents are in late-phase clinical development and are likely to enter the clinic in the near future.
As understanding of the underlying pathology of advanced prostate cancer is further elucidated, the importance of genetic testing (genomic and somatic) to identify biomarkers is playing an increasing role in risk assessment and treatment selection. However, many treatments lack definitive biomarkers and clinicians must rely on their understanding of current best-practice approaches to guide treatment selection for individual patients with advanced prostate cancer. Frequently updated guidelines, along with an increasing number of available agents and the rapid pace of new FDA approvals has challenged many busy clinicians in their ability to stay up to date with current best-practice treatment approaches, which in turn may negatively impact patient outcomes.
This activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced and metastatic prostate cancer.
Faculty
Head, Medical Oncology Section
Associate Director for Clinical Research and Deputy Director
University of Virginia Cancer Center
Co-Director Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia
Conflict of Interest Policy/Disclosure Statement
Dr. Dreicer has served on advisory boards for, Eisai, Janssen, Seattle Genetics, Genentech/Roche, Azuri, Astra Zeneca, Orion, and Novartis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University designates this enduring activity for a maximum of one (1.0)
nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.
Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This educational activity is supported by a medical education grant from Advanced Accelerator Applications, Astellas and Pfizer, Inc., Bayer Healthcare Pharmaceuticals, Inc., Exelixis, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Sanofi-Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: February 17, 2022
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Explain the different treatment modalities for treating advanced and metastatic prostate cancer including hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies
- Describe and implement the latest advances in the management of advanced prostate cancer across the disease continuum
- Personalize treatment decisions for patients with advanced and metastatic prostate cancer based on patient-specific factors, latest best-practice treatment strategies, recent clinical trial data, and expert recommendations
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementadvanced prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With the exception of skin cancer, prostate cancer remains the most common cause of cancer in American men. The majority of patients diagnosed will seek treatment through surgery or radiation, and among those patients, approximately one-third will experience disease recurrence as indicated by elevated prostate specific antigen (PSA). Although androgen deprivation therapy (ADT) achieves temporary tumor control or regression in 90% of these individuals, most patients will ultimately progress to the advanced and/or fatal stage of malignancy, known as castrate-resistant prostate cancer (CRPC), in which the disease spreads to the regional lymph nodes, seminal vesicles, and distant sites such as the bones.
In the past decade, the treatment landscape for advanced prostate cancer has changed dramatically with the introduction of various agents that have demonstrated a survival benefit. Many agents have received FDA approval for the treatment of advanced prostate cancer, including early taxanes, novel endocrine therapies that deprive or block prostate cancers from the effects of androgens, immunotherapeutic strategies that act to induce antitumor responses, new radiopharmaceuticals to target bony metastases, and novel targeted therapies. These agents are currently in clinical trials to assess their applicability to different phases of the treatment paradigm, either alone or in combination, in an effort to prolong survival while maintaining the patients’ quality of life. Other novel agents are in late-phase clinical development and are likely to enter the clinic in the near future.
As understanding of the underlying pathology of advanced prostate cancer is further elucidated, the importance of genetic testing (genomic and somatic) to identify biomarkers is playing an increasing role in risk assessment and treatment selection. However, many treatments lack definitive biomarkers and clinicians must rely on their understanding of current best-practice approaches to guide treatment selection for individual patients with advanced prostate cancer. Frequently updated guidelines, along with an increasing number of available agents and the rapid pace of new FDA approvals has challenged many busy clinicians in their ability to stay up to date with current best-practice treatment approaches, which in turn may negatively impact patient outcomes.
This activity aims to address these gaps in clinician knowledge to improve outcomes for patients with advanced and metastatic prostate cancer.
Faculty
Head, Medical Oncology Section
Associate Director for Clinical Research and Deputy Director
University of Virginia Cancer Center
Co-Director Mellon Urologic Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia
Conflict of Interest Policy/Disclosure Statement
Dr. Dreicer has served on advisory boards for, Eisai, Janssen, Seattle Genetics, Genentech/Roche, Azuri, Astra Zeneca, Orion, and Novartis
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University designates this enduring activity for a maximum of one (1.0)
nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.
Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This educational activity is supported by a medical education grant from Advanced Accelerator Applications, Astellas and Pfizer, Inc., Bayer Healthcare Pharmaceuticals, Inc., Exelixis, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Sanofi-Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Basal Cell Carcinoma: To Targeted Therapy and Beyond—Advanced Basal Cell Carcinoma: Navigating an Evolving Therapeutic Landscape
StartActivity Details
ABIM MOC Points
Expires: April 8, 2022
Jointly Provided By
Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Target Audience
This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with advanced basal cell carcinoma (BCC).
Learning Objectives
After completing this activity, the clinician should be able to:
- Apply current data to the appropriate selection of Hedgehog inhibitors in advanced basal cell carcinoma (BCC)
- Evaluate the role and place of immunotherapy in managing patients with advanced BCC
Activity Description
Therapeutic options for advanced basal cell carcinoma (BCC) have been transformed by the introduction of Hedgehog pathway inhibitors (HPIs) and the emergence of immunotherapy. Led by a multidisciplinary expert panel, this activity uniquely features an experienced patient sharing key insights from their treatment journey. The discussion focuses on the role and place of HPIs and PD-1 inhibitors in advanced BCC and provides professional guidance on managing class-specific toxicities, including immune-mediated adverse events.
Statement of Educational Need
Healthcare providers require expert insights on current safety and efficacy data to guide appropriate selection and use of Hedgehog pathway inhibitors in advanced basal cell carcinoma (BCC). The advent of immunotherapy necessitates education with respect to its role and place in the treatment armamentarium, as well as professional guidance on strategies to proactively identify and manage immune-related adverse events.
Chair
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA
Disclosure:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna
Faculty
Director, Oncodermatology Program
Professor of Dermatology
Memorial Sloan Kettering Cancer Center
New York City, NY
Disclosure:
Consultant Fees: Apricity, AstraZeneca, Azitra, Bicara, Deciphera, DFB, EMD Serono, F. Hoffmann-La Roche AG, Genentech, Innovaderm, Janssen, Johnson & Johnson, Kintara, Loxo, Lutris, NCODA, Novartis, Novocure, Oncoderm, OnQuality, QED, RBC/La Roche Posay, Roche, Seattle Genetics, Trifecta, Varsona
Research Funding: AstraZeneca, Johnson & Johnson, Lutris, Novartis, Novocure, OQL, Paxman, US Biotest, and is funded in part through NIH/NIAMS grant U01 AR077511 and the NIH/NCI Cancer Center Support Grant P30 CA008748
Nurse Practitioner, Medical Oncology (Cutaneous Malignancies)
The Angeles Clinic and Research Institute
Los Angeles, CA
Disclosure:
Consulting Fees: Boston BioMed, Sanofi/Regeneron
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.75 medical knowledge MOC points in
the American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
In order to claim MOC points, users must:
- Review and successfully complete the activity
- Proceed to the evaluation and provide your ABIM ID and date of birth
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation form and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.
Activity Details
ABIM MOC Points
Expires: April 8, 2022
Jointly Provided By
Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Target Audience
This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with advanced basal cell carcinoma (BCC).
Learning Objectives
After completing this activity, the clinician should be able to:
- Apply current data to the appropriate selection of Hedgehog inhibitors in advanced basal cell carcinoma (BCC)
- Evaluate the role and place of immunotherapy in managing patients with advanced BCC
Activity Description
Therapeutic options for advanced basal cell carcinoma (BCC) have been transformed by the introduction of Hedgehog pathway inhibitors (HPIs) and the emergence of immunotherapy. Led by a multidisciplinary expert panel, this activity uniquely features an experienced patient sharing key insights from their treatment journey. The discussion focuses on the role and place of HPIs and PD-1 inhibitors in advanced BCC and provides professional guidance on managing class-specific toxicities, including immune-mediated adverse events.
Statement of Educational Need
Healthcare providers require expert insights on current safety and efficacy data to guide appropriate selection and use of Hedgehog pathway inhibitors in advanced basal cell carcinoma (BCC). The advent of immunotherapy necessitates education with respect to its role and place in the treatment armamentarium, as well as professional guidance on strategies to proactively identify and manage immune-related adverse events.
Chair
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA
Disclosure:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna
Faculty
Director, Oncodermatology Program
Professor of Dermatology
Memorial Sloan Kettering Cancer Center
New York City, NY
Disclosure:
Consultant Fees: Apricity, AstraZeneca, Azitra, Bicara, Deciphera, DFB, EMD Serono, F. Hoffmann-La Roche AG, Genentech, Innovaderm, Janssen, Johnson & Johnson, Kintara, Loxo, Lutris, NCODA, Novartis, Novocure, Oncoderm, OnQuality, QED, RBC/La Roche Posay, Roche, Seattle Genetics, Trifecta, Varsona
Research Funding: AstraZeneca, Johnson & Johnson, Lutris, Novartis, Novocure, OQL, Paxman, US Biotest, and is funded in part through NIH/NIAMS grant U01 AR077511 and the NIH/NCI Cancer Center Support Grant P30 CA008748
Nurse Practitioner, Medical Oncology (Cutaneous Malignancies)
The Angeles Clinic and Research Institute
Los Angeles, CA
Disclosure:
Consulting Fees: Boston BioMed, Sanofi/Regeneron
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.75 medical knowledge MOC points in
the American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
In order to claim MOC points, users must:
- Review and successfully complete the activity
- Proceed to the evaluation and provide your ABIM ID and date of birth
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation form and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.
Unlocking Epigenetic Secrets from the Womb: Therapeutic Options for Advanced and Recurrent Endometrial Cancer
StartActivity Details
Expires: April 8, 2022
Accredited By
Provided by Integrity Continuing Education, Inc.
Statement of Commercial Support
Supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme Corp.
Target Audience
This program is intended for medical oncologists, gynecologic oncologists, primary care physicians, advanced practice providers, emergency department physicians, and pharmacists involved in the management and treatment of patients with endometrial cancer (EC).
Learning Objectives
- Identifyboth preventable and inescapable risk factors that drive mortality rates in advanced and recurrent EC
- Select appropriate and individualized treatment approaches for each EC patient based genomic subtypes and molecular markers
- Developa strategy for identifying and addressing adverse events caused by immunotherapy and/or combination treatments
- Incorporatea patient-centric treatment approach that considers each woman’s well-being and quality of life
Activity Description
Previously hidden epigenetic alterations of a more malevolent and disordered nature can result in EC, the most common gynecologic malignancy in the United States. Recent unraveling of the molecular profile of EC and its tumor microenvironment has revealed the immunologic nature of this disease, showing that up to 91% of patients with advanced or recurrent EC have at least one genetic mutation that can serve as an actionable therapeutic target. Indeed, unlocking the epigenetic secrets of advanced and recurrent EC has shown this disease to be highly immunogenic, making this gynecologic cancer an ideal candidate for immunotherapy. Consequently, immunotherapy with immune checkpoint inhibitors (ICIs) are being researched as both monotherapy and in synergistic combinations with cytotoxic, hormonal, and targeted treatments for greater efficacy and improved survival outcomes.
In this case-based activity, clinicians will have the opportunity to navigate a simulated patient case, making clinical decisions about diagnosis, testing, and treatment when prompted. Feedback regarding decisions made will be provided as they move through the case.
Faculty
Professor of Medicine
Brown University
Director, Women’s Cancers & Hematology-Oncology Outpatient Clinics
Lifespan Cancer Institute
Director, Medical Oncology & Oncology Sexual Health Program
Rhode Island Hospital
Providence, Rhode Island
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology & Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Don S. Dizon, MD, FACP, FASCO
Consulting Fees: AstraZeneca, Clovis, Regeneron
Contracted Research: Bristol-Myers Squibb, Kazia, Pfizer, Tesaro
(Institutional funds)
Shannon N. Westin, MD, MPH, has no real or apparent conflicts of interest to disclose.
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of April 8, 2021 through April 8, 2022 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.
Activity Details
Expires: April 8, 2022
Accredited By
Provided by Integrity Continuing Education, Inc.
Statement of Commercial Support
Supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme Corp.
Target Audience
This program is intended for medical oncologists, gynecologic oncologists, primary care physicians, advanced practice providers, emergency department physicians, and pharmacists involved in the management and treatment of patients with endometrial cancer (EC).
Learning Objectives
- Identifyboth preventable and inescapable risk factors that drive mortality rates in advanced and recurrent EC
- Select appropriate and individualized treatment approaches for each EC patient based genomic subtypes and molecular markers
- Developa strategy for identifying and addressing adverse events caused by immunotherapy and/or combination treatments
- Incorporatea patient-centric treatment approach that considers each woman’s well-being and quality of life
Activity Description
Previously hidden epigenetic alterations of a more malevolent and disordered nature can result in EC, the most common gynecologic malignancy in the United States. Recent unraveling of the molecular profile of EC and its tumor microenvironment has revealed the immunologic nature of this disease, showing that up to 91% of patients with advanced or recurrent EC have at least one genetic mutation that can serve as an actionable therapeutic target. Indeed, unlocking the epigenetic secrets of advanced and recurrent EC has shown this disease to be highly immunogenic, making this gynecologic cancer an ideal candidate for immunotherapy. Consequently, immunotherapy with immune checkpoint inhibitors (ICIs) are being researched as both monotherapy and in synergistic combinations with cytotoxic, hormonal, and targeted treatments for greater efficacy and improved survival outcomes.
In this case-based activity, clinicians will have the opportunity to navigate a simulated patient case, making clinical decisions about diagnosis, testing, and treatment when prompted. Feedback regarding decisions made will be provided as they move through the case.
Faculty
Professor of Medicine
Brown University
Director, Women’s Cancers & Hematology-Oncology Outpatient Clinics
Lifespan Cancer Institute
Director, Medical Oncology & Oncology Sexual Health Program
Rhode Island Hospital
Providence, Rhode Island
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology & Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Don S. Dizon, MD, FACP, FASCO
Consulting Fees: AstraZeneca, Clovis, Regeneron
Contracted Research: Bristol-Myers Squibb, Kazia, Pfizer, Tesaro
(Institutional funds)
Shannon N. Westin, MD, MPH, has no real or apparent conflicts of interest to disclose.
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of April 8, 2021 through April 8, 2022 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information for Questions About the Activity
For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.
HER2 Testing in Gastric Cancer: A Survival Guide to Interpretation and Application
StartActivity Details
Expires: April 1, 2022
Provided By
This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.
Target Audience
Oncology clinicians and other healthcare professionals who diagnose and/or manage patients with gastric cancer.
Learning Objectives
After completing this activity, the clinician should be able to:
- Assess current HER2 testing recommendations and strategies for gastric cancer
- Apply optimal testing and interpretation strategies to identify patients with gastric cancer that could benefit from HER2-directed therapy
- Identify current and emerging HER2-directed therapies for gastric cancer
Activity Description
In this activity, a panel of experts discuss current methods for determining the HER2 status of gastric adenocarcinomas and/or gastroesophageal junction cancers and the implications of these findings on treatment selection in the first-line setting and beyond.
Statement of Educational Need
HER2 testing volume has been found to be significantly lower in community-based centers than academic settings. Given the rapidly changing landscape of HER2 targeted therapy for the treatment of gastric cancer, it is essential to narrow the knowledge and testing gaps among clinicians who manage individuals with gastric adenocarcinomas or gastroesophageal cancers.
Activity Chair
Service Chief and Senior Staff, Gastrointestinal Oncology
H. Lee Moffitt Cancer Center
Professor, University of South Florida
Tampa, FL
Faculty
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
University of Chicago Medical Center
Chicago, IL
Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor, Pathology
Will Cornell Medical College
New York, NY
Conflict of Interest Policy/Disclosure Statement
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Richard Kim, MD, has affiliations with BMS, Lilly (Consultant); Bayer, BMS, Eisai (Contracted Research); Incyte (Speakers Bureau).
Daniel Catenacci, MD, has affiliations withAmgen, Archer & Natera, Astellas, BMS, Daiichi Sankyo, Lilly, Five Prime, Foundation Medicine, Guardant Health, Genentech/Roche, Gritstone, Merck, Pieris, QED, Taiho, Tempus, Zymeworks (Consultant); Genentech/Roche, Guardant Health, Lilly, Merck, Tempus (Speakers Bureau).
Laura H. Tang, MD, PhD, has no financial relationships to disclose.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse
Planner/Reviewer, has no financial relationships to
disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has
no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial
relationships.
RMEI Medical Education, LLC
Kim Farina, PhD, Medical Writer, has no financial
relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial
relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial
relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure
independence, balance, objectivity, scientific rigor, and integrity in all of
its continuing education activities. The author must disclose to the
participants any significant relationships with ineligible companies whose
products or devices may be mentioned in the activity or with the commercial
supporter of this continuing education activity. Identified conflicts of
interest are mitigated by AKH prior to accreditation of the activity. AKH
planners and reviewers have no relevant financial relationships to
disclose.
Disclosure of Unlabeled Use and Investigational
Product
This educational activity may include discussion of uses of agents that are
investigational and/or unapproved by the FDA. Please refer to the official
prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with
information to assist in his/her practice and professional development and is
not to be considered a diagnostic tool to replace professional advice or
treatment. The course serves as a general guide to the healthcare
professional, and therefore, cannot be considered as giving legal, nursing,
medical, or other professional advice in specific cases. AKH Inc. and RMEI
Medical Education, LLC specifically disclaim responsibility for any adverse
consequences resulting directly or indirectly from information in the course,
for undetected error, or through participant's misunderstanding of the
content.
Accreditation Statement
Credit
provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving
patient care, this activity has been planned and implemented by AKH Inc.,
Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc.,
Advancing Knowledge in Healthcare is jointly accredited by the Accreditation
Council for Continuing Medical Education (ACCME), the Accreditation Council
for Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity
for a maximum of 0.50 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Instructions for Receiving Credit
Fee Information
There is no fee for this educational activity.
Criteria For Success
In order to receive credit, participants must review the activity content and
successfully complete both the post-test and evaluation. A statement of
credit will be available to print immediately. You must score 70% or higher
on the post-test to receive credit for this activity.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Activity Details
Expires: April 1, 2022
Provided By
This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.
Target Audience
Oncology clinicians and other healthcare professionals who diagnose and/or manage patients with gastric cancer.
Learning Objectives
After completing this activity, the clinician should be able to:
- Assess current HER2 testing recommendations and strategies for gastric cancer
- Apply optimal testing and interpretation strategies to identify patients with gastric cancer that could benefit from HER2-directed therapy
- Identify current and emerging HER2-directed therapies for gastric cancer
Activity Description
In this activity, a panel of experts discuss current methods for determining the HER2 status of gastric adenocarcinomas and/or gastroesophageal junction cancers and the implications of these findings on treatment selection in the first-line setting and beyond.
Statement of Educational Need
HER2 testing volume has been found to be significantly lower in community-based centers than academic settings. Given the rapidly changing landscape of HER2 targeted therapy for the treatment of gastric cancer, it is essential to narrow the knowledge and testing gaps among clinicians who manage individuals with gastric adenocarcinomas or gastroesophageal cancers.
Activity Chair
Service Chief and Senior Staff, Gastrointestinal Oncology
H. Lee Moffitt Cancer Center
Professor, University of South Florida
Tampa, FL
Faculty
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
University of Chicago Medical Center
Chicago, IL
Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor, Pathology
Will Cornell Medical College
New York, NY
Conflict of Interest Policy/Disclosure Statement
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Richard Kim, MD, has affiliations with BMS, Lilly (Consultant); Bayer, BMS, Eisai (Contracted Research); Incyte (Speakers Bureau).
Daniel Catenacci, MD, has affiliations withAmgen, Archer & Natera, Astellas, BMS, Daiichi Sankyo, Lilly, Five Prime, Foundation Medicine, Guardant Health, Genentech/Roche, Gritstone, Merck, Pieris, QED, Taiho, Tempus, Zymeworks (Consultant); Genentech/Roche, Guardant Health, Lilly, Merck, Tempus (Speakers Bureau).
Laura H. Tang, MD, PhD, has no financial relationships to disclose.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:
AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse
Planner/Reviewer, has no financial relationships to
disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has
no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial
relationships.
RMEI Medical Education, LLC
Kim Farina, PhD, Medical Writer, has no financial
relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial
relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial
relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure
independence, balance, objectivity, scientific rigor, and integrity in all of
its continuing education activities. The author must disclose to the
participants any significant relationships with ineligible companies whose
products or devices may be mentioned in the activity or with the commercial
supporter of this continuing education activity. Identified conflicts of
interest are mitigated by AKH prior to accreditation of the activity. AKH
planners and reviewers have no relevant financial relationships to
disclose.
Disclosure of Unlabeled Use and Investigational
Product
This educational activity may include discussion of uses of agents that are
investigational and/or unapproved by the FDA. Please refer to the official
prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with
information to assist in his/her practice and professional development and is
not to be considered a diagnostic tool to replace professional advice or
treatment. The course serves as a general guide to the healthcare
professional, and therefore, cannot be considered as giving legal, nursing,
medical, or other professional advice in specific cases. AKH Inc. and RMEI
Medical Education, LLC specifically disclaim responsibility for any adverse
consequences resulting directly or indirectly from information in the course,
for undetected error, or through participant's misunderstanding of the
content.
Accreditation Statement
Credit
provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving
patient care, this activity has been planned and implemented by AKH Inc.,
Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc.,
Advancing Knowledge in Healthcare is jointly accredited by the Accreditation
Council for Continuing Medical Education (ACCME), the Accreditation Council
for Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity
for a maximum of 0.50 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Instructions for Receiving Credit
Fee Information
There is no fee for this educational activity.
Criteria For Success
In order to receive credit, participants must review the activity content and
successfully complete both the post-test and evaluation. A statement of
credit will be available to print immediately. You must score 70% or higher
on the post-test to receive credit for this activity.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions About the Activity
If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Clinical Strategies to Optimize Outcomes Across the Disease Spectrum in Multiple Myeloma
StartActivity Details
1.0 Contact Hour(s)
Expires: March 8, 2022
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.
Learning Objectives
After completing this program, participants should be able to:
- Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
- Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
- Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.
The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.
Faculty
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO
Conflict of Interest Policy/Disclosure Statement
Research Grant: Pharmacyclics
Consultant: Pharmacyclics
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
Activity Details
1.0 Contact Hour(s)
Expires: March 8, 2022
Accredited By
Rush University Medical Center
Co-Provided By
Target Audience
This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.
Learning Objectives
After completing this program, participants should be able to:
- Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
- Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
- Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.
Statement of Educational Need
With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.
The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.
Faculty
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO
Conflict of Interest Policy/Disclosure Statement
Research Grant: Pharmacyclics
Consultant: Pharmacyclics
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) AMA PRA Category 1 Credit(s)™.
Physicians/Physician Assistants/Nurse Practitioners should claim only credit
commensurate with the extent of their participation in the activity.
Nurse
Rush University Medical Center designates this enduring activity for a
maximum of one (1.0) nursing contact hour(s).
This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
Pharmacist
Rush University Medical Center designates this knowledge-based enduring
activity for a maximum of one (1.0) contact hour(s) for pharmacists.
Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
info@plexuscomm.com
On Topic Virtual Roundtable: Multidisciplinary Approaches and Thoughts on the Care of HER2+ Breast Cancer
StartActivity Details
Expires: February 28, 2022
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).
Learning Objectives
After participating in this activity, participants should be better able to:
- Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
- Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
- Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer
Activity Description
Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.
Statement of Educational Need
Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.
Agenda
Introduction & The Role of HER2 in Breast Cancer
It Takes a Village: Optimizing the Breast Cancer Care Team
Treating Metastatic HER2+ Breast Cancer
Mitigating and Managing Adverse Events
Key Takeaways
Moderator
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas
Faculty
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Patient Advocates & Breast Cancer Survivors
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Conflict of Interest Policy/Disclosure Statement
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty
Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology,
AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech,
Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen
Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis,
Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche,
Seattle Genetics, Syndax Pharmaceuticals
Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma
Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca,
Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics,
Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai
Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics
Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo
Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma
Biotechnology, Research to Practice, i3 Health
Patient Advocates & Breast Cancer
Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics,
Sanofi
Sheila McGlown
No relevant financial relationships to disclose.
Planning Committee
The following planning committee members have nothing to disclose except for
the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Accreditation Statement
In support
of improving patient care, this activity has been planned and
implemented by University of Nebraska Medical Center and Bio
Ascend. University of Nebraska Medical Center is jointly accredited by
the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: February 28, 2022
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).
Learning Objectives
After participating in this activity, participants should be better able to:
- Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
- Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
- Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer
Activity Description
Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.
Statement of Educational Need
Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.
Agenda
Introduction & The Role of HER2 in Breast Cancer
It Takes a Village: Optimizing the Breast Cancer Care Team
Treating Metastatic HER2+ Breast Cancer
Mitigating and Managing Adverse Events
Key Takeaways
Moderator
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas
Faculty
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Patient Advocates & Breast Cancer Survivors
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Conflict of Interest Policy/Disclosure Statement
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty
Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology,
AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech,
Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen
Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis,
Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche,
Seattle Genetics, Syndax Pharmaceuticals
Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma
Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca,
Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics,
Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai
Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics
Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo
Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma
Biotechnology, Research to Practice, i3 Health
Patient Advocates & Breast Cancer
Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics,
Sanofi
Sheila McGlown
No relevant financial relationships to disclose.
Planning Committee
The following planning committee members have nothing to disclose except for
the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Accreditation Statement
In support
of improving patient care, this activity has been planned and
implemented by University of Nebraska Medical Center and Bio
Ascend. University of Nebraska Medical Center is jointly accredited by
the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.
Contact Information for Questions About the Activity
info@bioascend.com
Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML
StartActivity Details
Expires: February 25, 2022
Accredited By
Target Audience
This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.
Learning Objectives
- Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
- Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
- Describe case scenarios in which maintenance therapy may become standard in the near future
- Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse
Activity Description
This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.
Statement of Educational Need
Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.
Faculty
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo,
ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable
Labs
Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene,
Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Astellas and Bristol Myers Squibb.
Activity Details
Expires: February 25, 2022
Accredited By
Target Audience
This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.
Learning Objectives
- Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
- Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
- Describe case scenarios in which maintenance therapy may become standard in the near future
- Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse
Activity Description
This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.
Statement of Educational Need
Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.
Faculty
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo,
ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable
Labs
Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene,
Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Astellas and Bristol Myers Squibb.
Optimizing Frontline Immunotherapy for High PD-L1 Expressers with NSCLC
StartActivity Details
ABIM MOC Points
Expires: February 23, 2022
Jointly Provided By
Jointly provided by Postgraduate institute for Medicine and RMEI Medical Education, LLC.
Target Audience
Oncologists and pulmonologists involved in the treatment of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
After completing this activity, the clinician should be able to:
- Analyze key safety and efficacy data for current and emerging frontline immunotherapy options in advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression levels ≥50%
- Assess the potential impact of emerging frontline immunotherapeutic approaches on treatment selection in patients with advanced NSCLC and high PD-L1 expression
Activity Description
The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of regimens targeting the PD-1/PD-L1 axis. In this activity, Roy S. Herbst, MD, PhD and Sarah B. Goldberg, MD, MPH, share the latest data for current and emerging checkpoint inhibitor monotherapies in advanced NSCLC with high PD-L1 expression and provide expert guidance on optimizing frontline treatment selection.
Activity Chair
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology
Associate Cancer Center Director, Translational Research
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT
Faculty
Associate Professor of Medicine (Medical Oncology)
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT
Conflict of Interest Policy/Disclosure Statement
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Roy S. Herbst, MD, PhD, has affiliations with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa Therapeutics, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc, Symphogen, Takeda, Tesaro, Tocagen, WindMIL Therapeutics, Xencor, Inc. (Consulting); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company (Contracted Research); Junshi Pharmaceuticals (Board Member).
Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Regeneron, Sanofi Genzyme (Consulting); AstraZeneca, Boehringer Ingelheim (ContractedResearch).
Planners and Managers
The PIM planners and managers have nothing to disclose. The RMEI Medical
Education, LLC, planners and managers have nothing to disclose.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners,
managers, and other individuals who are in a position to control the content
of this activity to disclose any real or apparent conflict of interest (COI)
they may have as related to the content of this activity. All identified COI
are thoroughly vetted and resolved according to PIM policy. PIM is committed
to providing its learners with high quality activities and related materials
that promote improvements or quality in healthcare and not a specific
proprietary business interest of a commercial interest.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside of
the labeled indications. The opinions expressed in the educational activity
are those of the faculty and do not necessarily represent the views of the
planners. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to serve
as a guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed or suggested in this activity
should not be used by clinicians without evaluation of their patient's
conditions and possible contraindications and/or dangers in use, review of
any applicable manufacturer's product information, and comparison with
recommendations of other authorities.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.5 medical knowledge MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
In order to claim MOC points, users must:
- Review and successfully complete the activity
- Proceed to the evaluation and provide your ABIM ID and date of birth
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation form and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Activity Details
ABIM MOC Points
Expires: February 23, 2022
Jointly Provided By
Jointly provided by Postgraduate institute for Medicine and RMEI Medical Education, LLC.
Target Audience
Oncologists and pulmonologists involved in the treatment of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
After completing this activity, the clinician should be able to:
- Analyze key safety and efficacy data for current and emerging frontline immunotherapy options in advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression levels ≥50%
- Assess the potential impact of emerging frontline immunotherapeutic approaches on treatment selection in patients with advanced NSCLC and high PD-L1 expression
Activity Description
The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of regimens targeting the PD-1/PD-L1 axis. In this activity, Roy S. Herbst, MD, PhD and Sarah B. Goldberg, MD, MPH, share the latest data for current and emerging checkpoint inhibitor monotherapies in advanced NSCLC with high PD-L1 expression and provide expert guidance on optimizing frontline treatment selection.
Activity Chair
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology
Associate Cancer Center Director, Translational Research
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT
Faculty
Associate Professor of Medicine (Medical Oncology)
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT
Conflict of Interest Policy/Disclosure Statement
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Roy S. Herbst, MD, PhD, has affiliations with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa Therapeutics, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc, Symphogen, Takeda, Tesaro, Tocagen, WindMIL Therapeutics, Xencor, Inc. (Consulting); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company (Contracted Research); Junshi Pharmaceuticals (Board Member).
Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Regeneron, Sanofi Genzyme (Consulting); AstraZeneca, Boehringer Ingelheim (ContractedResearch).
Planners and Managers
The PIM planners and managers have nothing to disclose. The RMEI Medical
Education, LLC, planners and managers have nothing to disclose.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners,
managers, and other individuals who are in a position to control the content
of this activity to disclose any real or apparent conflict of interest (COI)
they may have as related to the content of this activity. All identified COI
are thoroughly vetted and resolved according to PIM policy. PIM is committed
to providing its learners with high quality activities and related materials
that promote improvements or quality in healthcare and not a specific
proprietary business interest of a commercial interest.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside of
the labeled indications. The opinions expressed in the educational activity
are those of the faculty and do not necessarily represent the views of the
planners. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to serve
as a guideline for patient management. Any procedures, medications, or other
courses of diagnosis or treatment discussed or suggested in this activity
should not be used by clinicians without evaluation of their patient's
conditions and possible contraindications and/or dangers in use, review of
any applicable manufacturer's product information, and comparison with
recommendations of other authorities.
Joint Accreditation Statement
In support of improving
patient care, this activity has been planned and implemented by the
Postgraduate Institute for Medicine and RMEI Medical Education, LLC.
Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity, which includes participation in the evaluation component,
enables the participant to earn up to 0.5 medical knowledge MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM
MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
In order to claim MOC points, users must:
- Review and successfully complete the activity
- Proceed to the evaluation and provide your ABIM ID and date of birth
MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a
full-service medical education company. The winner will be selected via
automated random drawing on a quarterly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation form and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma CME
StartActivity Details
Expires: February 1, 2022
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
- Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
- Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
- Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
- Discuss clinical trials results that are investigating emerging novel agents in patients with MM
Activity Description
Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.
Statement of Educational Need
Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.
Faculty
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Conflict of Interest Policy/Disclosure Statement
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company,
Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm
Therapeutics, Merck & Co., Novartis
Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute,
Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen,
Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen,
Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics
Chair European Myeloma Network
Chair Hovon Myeloma Working Group
Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig
Steubing
UNMC: Brenda Ram, CMP, CHCP
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the University of Nebraska Medical Center and Bio Ascend. The University of
Nebraska Medical Center is jointly accredited by the Accreditation Council
for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: February 1, 2022
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.
Learning Objectives
After participating in this activity, participants should be better able to:
- Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
- Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
- Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
- Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
- Discuss clinical trials results that are investigating emerging novel agents in patients with MM
Activity Description
Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.
Statement of Educational Need
Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.
Faculty
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Conflict of Interest Policy/Disclosure Statement
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company,
Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm
Therapeutics, Merck & Co., Novartis
Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute,
Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen,
Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen,
Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics
Chair European Myeloma Network
Chair Hovon Myeloma Working Group
Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig
Steubing
UNMC: Brenda Ram, CMP, CHCP
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the University of Nebraska Medical Center and Bio Ascend. The University of
Nebraska Medical Center is jointly accredited by the Accreditation Council
for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.
Contact Information for Questions About the Activity
info@bioascend.com
Podium to Practice: Recent Clinical Trial Updates of Current and Emerging Approaches for the Treatment of Relapsed/Refractory Multiple Myeloma
StartActivity Details
Expires: January 28, 2022
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review currently available treatment options for patients with R/R MM, and the unmet need for novel approaches, agents, and combinations in this setting
- Evaluate the efficacy and safety of recently published clinical trial data of emerging agents and strategies being investigated in patients with R/R MM
- Assess strategies to incorporate novel therapies into practice as they become available
Faculty
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia
Associate Professor
Department of Medicine
University of California, San Francisco
San Francisco, California
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Conflict of Interest Policy/Disclosure Statement
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty
Sagar Lonial, MD, FACP
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company,
Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm
Therapeutics, Merck & Co., Novartis
Nina Shah, MD
Disclosures
Consulting Fees: bluebird bio, Inc., Celgene Corporation,
Janssen Oncology, Sutro Biopharma, Inc., TeneoBio
Contracted Research & Publishing: Amgen Inc., Bristol
Myers Squibb, CareDx, Genentech, Inc., GlaxoSmithKline LLC, Indapta
Therapeutics, Nektar Therapeutics, Precision BioSciences, Sanofi, Surface
Oncology
Ownership Interest: Indapta Therapeutics
Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig
Steubing
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the University of Nebraska Medical Center and Bio Ascend. The University of
Nebraska Medical Center is jointly accredited by the Accreditation Council
for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity is supported by independent educational grants from Karyopharm Therapeutics, Legend Biotech, and Sanofi Genzyme.
Contact Information for Questions About the Activity
info@bioascend.com
Activity Details
Expires: January 28, 2022
Accredited By
The University of Nebraska Medical Center
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Review currently available treatment options for patients with R/R MM, and the unmet need for novel approaches, agents, and combinations in this setting
- Evaluate the efficacy and safety of recently published clinical trial data of emerging agents and strategies being investigated in patients with R/R MM
- Assess strategies to incorporate novel therapies into practice as they become available
Faculty
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia
Associate Professor
Department of Medicine
University of California, San Francisco
San Francisco, California
Instructions for Receiving Credit
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Conflict of Interest Policy/Disclosure Statement
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
Faculty
Sagar Lonial, MD, FACP
Disclosures
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company,
Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm
Therapeutics, Merck & Co., Novartis
Nina Shah, MD
Disclosures
Consulting Fees: bluebird bio, Inc., Celgene Corporation,
Janssen Oncology, Sutro Biopharma, Inc., TeneoBio
Contracted Research & Publishing: Amgen Inc., Bristol
Myers Squibb, CareDx, Genentech, Inc., GlaxoSmithKline LLC, Indapta
Therapeutics, Nektar Therapeutics, Precision BioSciences, Sanofi, Surface
Oncology
Ownership Interest: Indapta Therapeutics
Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig
Steubing
Disclaimer Statement/Disclosure of Unlabeled Use
UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.
Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the University of Nebraska Medical Center and Bio Ascend. The University of
Nebraska Medical Center is jointly accredited by the Accreditation Council
for Continuing Medical Education (ACCME), the Accreditation Council for
Pharmacy Education (ACPE), and the American Nurses Credentialing Center
(ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Statement of Commercial Support
This activity is supported by independent educational grants from Karyopharm Therapeutics, Legend Biotech, and Sanofi Genzyme.
Contact Information for Questions About the Activity
info@bioascend.com